Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

GlobeNewswire May 10, 2017

Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update

GlobeNewswire May 4, 2017

Ultragenyx to Host Conference Call for First Quarter 2017 Financial Results and Corporate Update

GlobeNewswire April 28, 2017

Ultragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders

GlobeNewswire April 27, 2017

Research Reports Coverage on Biotech Stocks -- Ultragenyx Pharma, Chimerix, Coherus Biosciences, and Omeros

PR Newswire April 27, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  April 19, 2017

Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors

GlobeNewswire April 10, 2017

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  April 6, 2017

Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia

GlobeNewswire April 6, 2017

15 Biggest Mid-Day Losers For Thursday

Benzinga.com  March 23, 2017

Wedbush Lowers Ultragenyx Pharmaceutical Price Target On New Outlook

Benzinga.com  March 23, 2017

The Market In 5 Minutes

Benzinga.com  March 23, 2017

Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study

GlobeNewswire March 22, 2017

Research Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx Pharma, Cymabay Therapeutics, and Omeros

PR Newswire March 17, 2017

PriceWatch Alert: High return covered-call trades for Cliffs Natural Resources, JD.com, Realty Income, Ultragenyx Pharmaceuticals and YY

PR Newswire March 3, 2017

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire March 2, 2017

Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update

GlobeNewswire February 16, 2017

Ultragenyx to Present at Leerink Partners Global Healthcare Conference

GlobeNewswire February 10, 2017

Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2016 Financial Results and Corporate Update

GlobeNewswire February 9, 2017

Research Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire January 30, 2017